AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6808542 — intervention group
Group type: COMPARATOR
Intervention: Low nicotine content (0.2 mg) cigarette
Number of subjects: 0
Study 30465630 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth technology‐enabled, nurse‐guided intervention with a Blue-toothed BP device and smartphone App for monitoring BP measurements and medication intake for three months
Number of subjects: 60
Study 30465630 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study 30465630 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth technology‐enabled, nurse‐guided intervention
Number of subjects: 60
Study 28316162 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm/d group
Number of subjects: 104
Study 28316162 — intervention group
Group type: COMPARATOR
Intervention: 4 mm/d group
Number of subjects: 104
Study 25822674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radioisotope and blue dye
Number of subjects: 667
Study 25822674 — intervention group
Group type: COMPARATOR
Intervention: Radioisotope alone
Number of subjects: 667
Study 24054830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg once daily (qd) for 7 days (n=6)
Number of subjects: 25
Study 24054830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 65 mg once daily (qd) for 7 days (n=6)
Number of subjects: 25
Study 24054830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg twice daily (bid) for 7 days (n=6)
Number of subjects: 25
Study 24054830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 25
Study 21383294 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (oxaliplatin 130 mg/m² on day 1 plus capecitabine 1,000 mg/m² twice daily on days 1 to 14 every 3 weeks for 24 weeks)
Number of subjects: 1886
Study 21383294 — intervention group
Group type: COMPARATOR
Intervention: FU/FA (bolus fluorouracil and folinic acid for 24 weeks or 32 weeks)
Number of subjects: 1886
Study 21383294 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 1886
Study 21383294 — intervention group
Group type: COMPARATOR
Intervention: FU/FA
Number of subjects: 1886
Study 19698013 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose transdermal scopolamine patches
Number of subjects: 20
Study 19698013 — intervention group
Group type: COMPARATOR
Intervention: Single transdermal scopolamine patch plus placebo patch
Number of subjects: 20
Study 17416271 — intervention group
Group type: EXPERIMENTAL
Intervention: MWM intervention
Number of subjects: 26
Study 17416271 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 26
Study 12669206 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical zipper (Medizip)
Number of subjects: 83
Study 12669206 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutaneous sutures (Control)
Number of subjects: 83
Study 11074745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium, 40 mg/d
Number of subjects: 1130
Study 11074745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study 9402072 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (injections of testosterone esters and transcutaneous patches)
Number of subjects: 0
Study 9402072 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 0
Study 1553580 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha alone
Number of subjects: 0
Study 1553580 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha combined with IFN-gamma
Number of subjects: 0
Study 1553580 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha and TNF-alpha
Number of subjects: 0
Study 3963017 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg per day (administered three times daily)
Number of subjects: 90
Study 3963017 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg per day (administered twice daily)
Number of subjects: 90
Study 3963017 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 90
Study 3963017 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg per day
Number of subjects: 90
Study 29967045 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 4733
Study 29967045 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 4733
Study 26493492 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib
Number of subjects: 31
Study 26493492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24818182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-containing cleanser and moisturizer regimen
Number of subjects: 151
Study 22205149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 489
Study 22205149 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 489
Study 22205149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy with calcitriol
Number of subjects: 489
Study 22205149 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms of estrogen receptor α
Number of subjects: 489
Study 22205149 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms of vitamin D receptor
Number of subjects: 489
Study 20638901 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 283
Study 20638901 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 283
Study 20638901 — intervention group
Group type: EXPERIMENTAL
Intervention: TLH
Number of subjects: 283
Study 20638901 — intervention group
Group type: COMPARATOR
Intervention: TAH
Number of subjects: 283
Study 18433525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 60
Study 15964329 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 20
Study 15964329 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 20
Study 11788660 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg every 8 h for 7 d)
Number of subjects: 6
Study 10235511 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 6026 at 120 mg/day for 21 days
Number of subjects: 49
Study 10235511 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 6026 at 150 mg/day for >19 days
Number of subjects: 49
Study 10235511 — intervention group
Group type: EXPERIMENTAL
Intervention: WR 6026
Number of subjects: 49
Study 8767368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen administration
Number of subjects: 22
Study 2024744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block with 0.5% bupivacaine and adrenaline (0.3 ml/kg)
Number of subjects: 29
Study 2024744 — intervention group
Group type: COMPARATOR
Intervention: Conventional opioid analgesia (control group)
Number of subjects: 29
Study 7014058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 600 mg, b.i.d.
Number of subjects: 75
Study 7014058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and hydroxychloroquine (Plaquenil), 300 mg, b.i.d.
Number of subjects: 75
Study 7014058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31259390 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-based classifier using a nanomaterial-based sensor array
Number of subjects: 726
Study 28966304 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (34‐36°C)
Number of subjects: 20
Study 28966304 — intervention group
Group type: COMPARATOR
Intervention: Control group (without mild hypothermia therapy)
Number of subjects: 20
Study 25467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg + morphine 60 mg
Number of subjects: 18
Study 25467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) placebo + morphine 60 mg
Number of subjects: 18
Study 25467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg + morphine placebo
Number of subjects: 18
Study 25467190 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin enacarbil (GEn) alone
Number of subjects: 18
Study 25467190 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 18
Study 25467190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (GEn + morphine)
Number of subjects: 18
Study 23780900 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (4 min at -110 °C)
Number of subjects: 10
Study 23780900 — intervention group
Group type: COMPARATOR
Intervention: Cold water immersion (8 °C)
Number of subjects: 10
Study 21317209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing CPP-ACP paste (MI Paste Plus) with Transbond XT
Number of subjects: 66
Study 21317209 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoride CPP-ACP paste (MI Paste) with Transbond XT
Number of subjects: 66
Study 21317209 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment with etch-and-rinse adhesive system (Transbond XT)
Number of subjects: 66
Study 21317209 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment with self-etching adhesive system (Transbond Plus)
Number of subjects: 66
Study 21317209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing CPP-ACP paste (MI Paste Plus) with Transbond Plus
Number of subjects: 66
Study 21317209 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoride CPP-ACP paste (MI Paste) with Transbond Plus
Number of subjects: 66
Study 19653749 — intervention group
Group type: EXPERIMENTAL
Intervention: Action execution with visual go signal inducing apparent rotational motion (clockwise or counterclockwise)
Number of subjects: 0
Study 19653749 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants prepared manipulation actions but signaled their stimulus detections with a foot response
Number of subjects: 0
Study 17845276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100-400 mg/day)
Number of subjects: 48
Study 17845276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 14693611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 34
Study 14693611 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 34
Study 12067142 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drug for 24 weeks
Number of subjects: 302
Study 12067142 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 24 weeks
Number of subjects: 302
Study 12067142 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension study
Number of subjects: 302
Study 12067142 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attrition during 50-week period
Number of subjects: 302
Study 9526939 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 61
Study 9526939 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 61
Study 8009700 — intervention group
Group type: COMPARATOR
Intervention: Intensive multidisciplinary functional restoration program (project A)
Number of subjects: 238
Study 8009700 — intervention group
Group type: COMPARATOR
Intervention: Intensive multidisciplinary functional restoration program (project B)
Number of subjects: 238
Study 8009700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary functional restoration program
Number of subjects: 238
Study 2570956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (120 mg/kg/day)
Number of subjects: 161
Study 2570956 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (chloramphenicol 100 mg/kg/day, doxycycline 4 mg/kg/day, trimethoprim 10 mg/kg/day, and sulphamethoxazole 50 mg/kg/day)
Number of subjects: 161
Study 434310 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 160
Study 434310 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine (Atabrine)
Number of subjects: 160
Study 31397128 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 31397128 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid sodium eye drops
Number of subjects: 60
Study 28524705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive individualized nutritional and educational interventions during the entire course of chemotherapy
Number of subjects: 144
Study 28524705 — intervention group
Group type: COMPARATOR
Intervention: Basic nutrition care and health education during hospitalization
Number of subjects: 144
Study 25039574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) with salbutamol and prednisolone
Number of subjects: 347
Study 25039574 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol and prednisolone alone (Control)
Number of subjects: 347
Study 23777201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Treatment (HIT)
Number of subjects: 300
Study 23777201 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Treatment (LIT)
Number of subjects: 300
Study 21864343 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AS+PQ (single dose 0.75 mg/kg)
Number of subjects: 3457
Study 21864343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3457
Study 19722772 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine + Deferiprone (n=35)
Number of subjects: 70
Study 19722772 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (n=35)
Number of subjects: 70
Study 17869635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg
Number of subjects: 3494
Study 17869635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 3494
Study 17869635 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3494
Study 17869635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate and Enoxaparin
Number of subjects: 3494
Study 16855074 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 1.25 mg
Number of subjects: 66
Study 16855074 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 5 mg
Number of subjects: 66
Study 16855074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16855074 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (1.25 mg or 5 mg)
Number of subjects: 66
Study 12773727 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM based self help manuals and sessions with an interactive computer program
Number of subjects: 918
Study 12773727 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 918
Study 10426879 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (Simvastatin)
Number of subjects: 3
Study 10426879 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (not specified)
Number of subjects: 3
Study 10426879 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (Pravastatin)
Number of subjects: 3
Study 7482385 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg
Number of subjects: 16
Study 7482385 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg
Number of subjects: 16
Study 7482385 — intervention group
Group type: COMPARATOR
Intervention: Dextroamphetamine 15 mg
Number of subjects: 16
Study 7482385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1951176 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 200 mg/m2, 5-fluorouracil (FU) 600 mg/m2, folinic acid (FA) 200 mg/m2, administered every 2 weeks
Number of subjects: 30
Study 1951176 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of the treatment
Number of subjects: 30
Study 7056271 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15
Study 7056271 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 7056271 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 15
Study 28533100 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) treatment, performed twice a day for 6 weeks
Number of subjects: 50
Study 28533100 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27914656 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group)
Number of subjects: 299
Study 27914656 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg twice daily titrated to 50 mg twice daily (pharmacokinetic-titration group)
Number of subjects: 299
Study 27914656 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic-titration group
Number of subjects: 299
Study 27914656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 23329162 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical mallet
Number of subjects: 46
Study 23329162 — intervention group
Group type: COMPARATOR
Intervention: Hand mallet (Control)
Number of subjects: 46
Study 23329162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Electrical mallet and Hand mallet)
Number of subjects: 46
Study 24895719 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (structured formative course)
Number of subjects: 185
Study 24895719 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 185
Study 20664616 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid enriched eggs
Number of subjects: 20
Study 20664616 — intervention group
Group type: EXPERIMENTAL
Intervention: organic eggs
Number of subjects: 20
Study 20664616 — intervention group
Group type: COMPARATOR
Intervention: no egg control
Number of subjects: 20
Study 18332454 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible PDFs with neutral pH and low glucose degradation products (GDPs)
Number of subjects: 104
Study 18332454 — intervention group
Group type: COMPARATOR
Intervention: Conventional PDFs
Number of subjects: 104
Study 16105530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg of calcitriol twice per day (group A)
Number of subjects: 417
Study 16105530 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg of calcitriol twice per day (group B)
Number of subjects: 417
Study 16105530 — intervention group
Group type: COMPARATOR
Intervention: No calcitriol (group C)
Number of subjects: 417
Study 11834648 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen during exercise
Number of subjects: 17
Study 11834648 — intervention group
Group type: COMPARATOR
Intervention: Air during exercise
Number of subjects: 17
Study 10512314 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 132
Study 10512314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 10512314 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Placebo
Number of subjects: 132
Study 7726258 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium-stained amniotic fluid (n = 28)
Number of subjects: 56
Study 7726258 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meconium-stained amniotic fluid, n = 28)
Number of subjects: 56
Study 2047050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose triphasic oral contraceptives (ethinyl estradiol and levonorgestrel)
Number of subjects: 57
Study 2047050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose triphasic oral contraceptives (ethinyl estradiol and norethindrone)
Number of subjects: 57
Study 2047050 — intervention group
Group type: COMPARATOR
Intervention: Control (nonhormonal contraception)
Number of subjects: 57
Study 6110089 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen/gestagen treatment
Number of subjects: 94
Study 6110089 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 94
Study 6110089 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of hormone therapy
Number of subjects: 94
Study 31269644 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain breaks activities (5 minutes per session for four months)
Number of subjects: 335
Study 31269644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brain breaks)
Number of subjects: 335
Study 26345405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (n = 25)
Number of subjects: 49
Study 26345405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 24)
Number of subjects: 49
Study 25761430 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg p.d.)
Number of subjects: 210
Study 25761430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (750 mg b.i.d.)
Number of subjects: 210
Study 22759620 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) integrated into EHR
Number of subjects: 70
Study 22759620 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 70
Study 21323491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy at dose step 4
Number of subjects: 157
Study 21323491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy at dose steps -2 and -1 (combined)
Number of subjects: 157
Study 21323491 — intervention group
Group type: COMPARATOR
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy (all dose steps)
Number of subjects: 157
Study 20306761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical medicine (not specified)
Number of subjects: 0
Study 20306761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert pill)
Number of subjects: 0
Study 20306761 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically active drugs (not specified)
Number of subjects: 0
Study 20306761 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs (not specified)
Number of subjects: 0
Study 17093247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 210
Study 17093247 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 210
Study 18210737 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg/day for 3 months
Number of subjects: 38